1. Fournier A, Arnaud CD, Johnson WJ, Taylor WF, Goldsmith RS. Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. II. Factors affecting serum immunoreactive parathyroid hormone. J Clin Invest 1971; 50: 599–605.
2. Fournier A, Moriniere P, Sebert JL, Dkhissi H, Atik A, Lefron P, Renaud H, Gueris J, Gregoire I, Idrissi A, Garabedian M. Calcium carbonate, an aluminum-free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathydoidism in uremia. Kidney Int 1986; 29: s114-s119.
3. Schneider HW, Kulbe KD, Weber H, Streicher E. In vitro and in vivo studies with a non-aluminum phosphate-binding compound. Kidney Int 1986; 28: s120-s123.
4. Moriniere P, Roussel A, Tahiri Y, de Fremont JF, Maurel G, Jaudon MC, Gueris J, Fournier A. Substitution of aluminum hydroxide by high doses of calcium carbonate in patients on chronic haemodialysis. proc EDTA 1982; 19: 784–787.
5. Slatopolsky E, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus D, Delmez J. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing hemodialysis. New Engl J Med 1986; 315: 157–161.